NEW ORLEANS -- The investigational oral PCSK9 inhibitor enlicitide reduced low-density lipoprotein (LDL) cholesterol in ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

In recent days, Merck announced pivotal Phase 3 trial results showing its once-daily oral PCSK9 inhibitor, enlicitide, ...

The cholesterol medication alirocumab, a PCSK9 inhibitor, combined with a statin appeared to reduce LDL cholesterol levels by ...

A new Merck pill called enlicitide slashes levels of harmful LDL cholesterol by up to 60%, similar to injectable PCSK9 drugs ...

An oral agent is needed because some patients don’t like injectables, and some doctors don’t prescribe them, experts say.

A new pill from Merck could change how millions of people treat high cholesterol and help prevent heart attacks and strokes ...

"These findings suggest that while PCSK9 inhibitors are safe and effective at lowering lipids, their impact on early vascular remodeling in heart transplant recipients may be limited -- at least ...

A novel once-daily oral PCSK9 inhibitor lowered LDL by up to 60% at 24 weeks in patients with heart disease or at high risk ...

THURSDAY, Nov. 13, 2025 (HealthDay News) — A new pill from Merck could change how millions of people treat high cholesterol ...

The cholesterol-lowering medication alirocumab, a PCSK9 inhibitor, along with a statin, lowered LDL cholesterol levels more than 50% in patients after a heart transplant, compared to those taking a ...

When compared to published data with inclisiran, a small interfering RNA (siRNA) molecule that inhibits production of the PCSK9 enzyme, the data showed lipid lowering for LDL-C, non-HDL-C, ApoB, and ...